March 28, 2025 07:30 AM EDT

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

Kyle LaHucik

Senior Reporter

Novo Nordisk is going all-in on next-generation obesity medicines, and on Friday announced a licensing deal with a Texas biotech to get access to its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Sanofi continues its bet on R&D by poaching GSK’s head of development

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

Senior Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B